PMID- 17241097
OWN - NLM
STAT- MEDLINE
DCOM- 20070521
LR  - 20170214
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 6
IP  - 1
DP  - 2007 Feb
TI  - 3D-segmentation of the 18F-choline PET signal for target volume definition in 
      radiation therapy of the prostate.
PG  - 23-30
AB  - Volumetric assessment of PET signals becomes increasingly relevant for 
      radiotherapy (RT) planning. Here, we investigate the utility of 18F-choline PET 
      signals to serve as a structure for semi-automatic segmentation for forward 
      treatment planning of prostate cancer. 18F-choline PET and CT scans of ten 
      patients with histologically proven prostate cancer without extracapsular growth 
      were acquired using a combined PET/CT scanner. Target volumes were manually 
      delineated on CT images using standard software. Volumes were also obtained from 
      18F-choline PET images using an asymmetrical segmentation algorithm. PTVs were 
      derived from CT 18F-choline PET based clinical target volumes (CTVs) by automatic 
      expansion and comparative planning was performed. As a read-out for dose given to 
      non-target structures, dose to the rectal wall was assessed. Planning target 
      volumes (PTVs) derived from CT and 18F-choline PET yielded comparable results. 
      Optimal matching of CT and 18F-choline PET derived volumes in the lateral and 
      cranial-caudal directions was obtained using a background-subtracted signal 
      thresholds of 23.0+/-2.6%. In antero-posterior direction, where adaptation 
      compensating for rectal signal overflow was required, optimal matching was 
      achieved with a threshold of 49.5+/-4.6%. 3D-conformal planning with CT or 
      18F-choline PET resulted in comparable doses to the rectal wall. Choline PET 
      signals of the prostate provide adequate spatial information amendable to 
      standardized asymmetrical region growing algorithms for PET-based target volume 
      definition for external beam RT.
FAU - Ciernik, I Frank
AU  - Ciernik IF
AD  - Center for Clinical Research, Zurich University Hospital, Zurich, Switzerland. 
      ciernik@iosi.ch
FAU - Brown, Derek W
AU  - Brown DW
FAU - Schmid, Daniel
AU  - Schmid D
FAU - Hany, Thomas
AU  - Hany T
FAU - Egli, Peter
AU  - Egli P
FAU - Davis, J Bernard
AU  - Davis JB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (fluoromethylcholine)
RN  - N91BDP6H0X (Choline)
SB  - IM
MH  - Choline/*analogs & derivatives
MH  - Humans
MH  - Imaging, Three-Dimensional
MH  - Male
MH  - *Positron-Emission Tomography
MH  - Prostate/*diagnostic imaging
MH  - Prostatic Neoplasms/*diagnostic imaging/*radiotherapy
MH  - Radiotherapy Planning, Computer-Assisted/*methods
EDAT- 2007/01/24 09:00
MHDA- 2007/05/22 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/05/22 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - d=3029&c=4222&p=15536&do=detail [pii]
AID - 10.1177/153303460700600104 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2007 Feb;6(1):23-30. doi: 10.1177/153303460700600104.